Slide 1: 9M and Q3 2025 Results
9M and Q3 2025 Results Conference call and webcast for investors and analysts 6 November 2025
Slide 2: Cautionary statements regarding forward-looking statements
Cautionary statements regarding forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certai
Slide 3: Conference call agenda
9M and Q3 2025 Results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Haematology Dave Fredrickson Susan Galbraith EVP, Oncology Haematology Business EVP, Oncology Haematology R&D BioPharmaceuticals R
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 4
Slide 5: Continued strong commercial performance in 9M 2025 and unprecedented pipeline delivery
Continued strong commercial performance in 9M 2025 and unprecedented pipeline delivery Sustained commercial Delivered high-impact momentum readouts 6 plenary +11% Total Revenue1 31 new approvals 16 positive presentations at in key regions Phase III readouts +15% Core EPS1 since FY 2024 results2 sinc
Slide 6: 9M 2025 – growth driven by global reach and diverse sources of business
9M 2025 – growth driven by global reach and diverse sources of business +16% 9M 2025 | % Total Revenue by therapy area +8% V&I: 826 +2% R&I: +13% Oncology CVRM R&I V&I Other Rare Disease Strength across 6,493 +6% 43% 23% 15% 2% 2% 16% therapy areas 9M 2025 | Total Revenue ($m)1 +5% CVRM: 18,591 9,80
Slide 7: Continued momentum delivering across diverse pipeline
Continued momentum delivering across diverse pipeline Key Phase III trial readouts in 2025 to date drive growth to 2030 and beyond Oncology BioPharmaceuticals Rare Disease NME NME SERENA-6 POTOMAC KALOS/LOGOS CARES camizestrant Imfinzi Breztri anselamimab NME NME MATTERHORN DESTINY-Breast11 PREVAIL
Slide 8: Strengthening operations in US to power future growth
Strengthening operations in US to power future growth Investments support $80bn Total Revenue ambition by 2030 – Provides greater clarity around pricing and 3-year exemption Expanding manufacturing Voluntary from tariffs footprint in US agreement with – MFN pricing for existing medicines in Medicaid
Slide 9: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER 9
Slide 10: 9M and Q3 2025 – Reported profit and loss
9M and Q3 2025 – Reported profit and loss 9M 2025 CER change % Total Q3 2025 CER change % Total $m % Revenue $m % Revenue - Product Sales 41,035 9 95 14,365 9 95 - Alliance Revenue 2,108 41 5 815 44 5 Product Revenue 43,143 11 100 15,180 11 100 - Collaboration Revenue 93 (15) - 11 (82) - Total Reven
Slide 11: 9M and Q3 2025 – Core profit and loss
9M and Q3 2025 – Core profit and loss 9M 2025 CER change % Total Q3 2025 CER change % Total $m % Revenue $m % Revenue - Product Sales 41,035 9 95 14,365 9 95 - Alliance Revenue 2,108 41 5 815 44 5 Product Revenue 43,143 11 100 15,180 11 100 - Collaboration Revenue 93 (15) - 11 (82) - Total Revenue 4
Slide 12: FY 2025 guidance reiterated
FY 2025 guidance reiterated Net cash inflow from operating activities increased by 37% in 9M 2025 Net debt/EBITDA 1.2x FY 2025 guidance (CER) $bn Total Revenue 1.0 anticipated to increase by a high single-digit percentage 5.0 12.2 Core EPS 3.6 anticipated to increase by a low double-digit percentage
Slide 13: Oncology
Oncology Dave Fredrickson ONCOLOGY HAEMATOLOGY BUSINESS Susan Galbraith ONCOLOGY HAEMATOLOGY R&D 13
Slide 14: Oncology – 9M and Q3 2025
Oncology – 9M and Q3 2025 Total Revenue +16% in 9M 2025 driven by strong global demand across medicines Oncology Q3 2025: key dynamics 9M 2025 $18.6bn, +16% • Tagrisso +10%, demand across indications, leadership in 1L combination market 7,000 • Calquence +11%, solidified position as leading BTKi in
Slide 15: Oncology – paradigm-shifting Phase III data presentations
Oncology – paradigm-shifting Phase III data presentations Data at ESMO reinforce our ambition to transform care in breast and bladder cancers Driving new approaches in Redefining care across breast cancer bladder cancer Moving Enhertu into early Broadening potential Moving Imfinzi into HER2+ breast
Slide 16: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Sharon Barr BIOPHARMACEUTICALS R&D 16
Slide 17: BioPharmaceuticals – 9M and Q3 2025
BioPharmaceuticals – 9M and Q3 2025 Total Revenue $17.1bn in 9M 2025 driven by strong momentum in key medicines CVRM R&I Q3 2025: key dynamics 9M 2025 $9.8bn, +5% 9M 2025 $6.5bn, +13% • Farxiga +8%, global demand growth 3,500 2,500 mainly driven by CKD and HF 3,000 • Lokelma +30%, market leader in g
Slide 18: BioPharmaceuticals – best-in-class profile with baxdrostat
BioPharmaceuticals – best-in-class profile with baxdrostat Potential first-in-class aldosterone inhibitor for uncontrolled and resistant hypertension BaxHTN Phase III data at ESC | Robust mmHg reduction with baxdrostat in Positive Bax24 readout uncontrolled and treatment resistant hypertension Chang
Slide 19: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION 19
Slide 20: Rare Disease – 9M and Q3 2025
Rare Disease – 9M and Q3 2025 Total Revenue $6.8bn in 9M 2025 driven by patient demand across the portfolio Rare Disease Q3 2025: key dynamics 9M 2025 $6.8bn, +6% 2,500 C5 Franchise • Ultomiris +17%, demand growth across indications, including within 2,000 the competitive gMG and PNH markets • Solir
Slide 21: Rare Disease – Phase III data and progress to date
Rare Disease – Phase III data and progress to date Reinforcing innovation and leadership in Rare Disease PREVAIL Phase III data at AANEM | Rapid, complete and sustained complement inhibition with gefurulimab in gMG Key Phase III progress in 2025 LS mean change (95% CI) from RCT baseline in MG-ADL to
Slide 22: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER 22
Slide 23: Executing in unprecedented catalyst rich period and on track for 2030 ambition
Executing in unprecedented catalyst rich period and on track for 2030 ambition H1 2025 H2 2025 H1 2026 H2 2026 DESTINY-Breast09 | Enhertu TROPION-Breast02 | Datroway AVANZAR | Datroway + Imfinzi TROPION-Lung15 | Datroway ± 1L HER2+ breast cancer 1L TNBC 1L NSQ/NSQ TROP2+ NSCLC Tagrisso 2L EGFRm NSCL
Slide 24: Investing in transformative technologies to underpin our next wave of growth beyond 2030
Investing in transformative technologies to underpin our next wave of growth beyond 2030 Weight management ADCs and Cell therapy and Gene therapy and Next-gen IO bispecifics and risk factors Radioconjugates T-cell engagers gene editing Establish and lead Develop scalable cell Replace systemic Make c
Slide 25: Q&A Session
Q&A Session Pascal Soriot Aradhana Sarin CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER Marc Dunoyer Susan Galbraith CHIEF EXECUTIVE EVP, ONCOLOGY HAEMATOLOGY R&D OFFICER, ALEXION Dave Fredrickson Sharon Barr EVP, ONCOLOGY EVP, BIOPHARMACEUTICALS R&D HAEMATOLOGY BUSINESS Ruud Dobber Iskra Reic EVP,
Slide 26: Appendix
Appendix
Slide 27: AstraZeneca P&L reference table
AP P E ND I X | P&L definitions AstraZeneca P&L reference table P&L line-item definitions P&L line-item definition Product Sales • Recognises sales from territories where Group has lead commercialisation • Recognises supply of Beyfortus to Sanofi Alliance Revenue • Alliance Revenue comprises income
Slide 28: AstraZeneca in non-small cell lung cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in non-small cell lung cancer Resectable Unresectable Metastatic Stg. I Stg. II-III Stg. I-II Stg. III 1L 2L 3L+ Est. epi (G7, 2025) ~150K ~70K ~50K ~100K ~310K ~190K ~70K Imfinzi CRT → Imfinzi Imfinzi + Imjudo + CTx POSEIDON AEGEAN PACIFIC Datroway +
Slide 29: AstraZeneca in breast cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in breast cancer Early Metastatic Neoadjuvant Adjuvant 1st line 2nd line 3rd line 4th line + Est. epi (G7, 2025) 540k 135k 100k 75k 60k HER2-positive Enhertu → THP NST→ residual disease → Enhertu Enhertu ± pertuzumab Enhertu Enhertu 15-20% DESTINY-Bre
Slide 30: AstraZeneca in gastric cancer
AP P E ND I X | Oncology tumour maps AstraZeneca in gastric cancer Early Advanced/Metastatic Stage II/III 1st line 2nd line 3rd line Est. epi (G7, 2025) 50k 90k 60k 30k Enhertu + rilvegostomig + FP HER2-positive ARTEMIDE-Gastric01 Enhertu Enhertu 20% DESTINY-Gastric02, 04 DESTINY-Gastric01 Enhertu +
Slide 31: Oncology
AP P E ND I X | Product Revenue Performance Oncology Tagrisso Lynparza 10% growth at CER to $5,352m in 9M 2025 7% growth at CER to $2,401m in 9M 2025 2,000 900 1,800 800 1,600 700 1,400 600 Product Revenue ($m) Product Revenue ($m) 1,200 500 1,000 400 800 300 600 400 200 200 100 0 0 Q3 Q4 Q1 Q2 Q3 Q
Slide 32: Oncology
AP P E ND I X | Product Revenue Performance Oncology Imfinzi Imjudo 25% growth at CER to $4,317m in 9M 2025 21% growth at CER to $253m in 9M 2025 1,800 100 90 1,600 80 1,400 70 1,200 Product Revenue ($m) Product Revenue ($m) 60 1,000 50 800 40 600 30 400 20 200 10 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3 Q
Slide 33: Oncology
AP P E ND I X | Product Revenue Performance Oncology Calquence Enhertu 10% growth at CER to $2,551m in 9M 2025 38% growth at CER to $1,976m in 9M 2025 1,000 800 900 700 800 600 700 Product Revenue ($m) Product Revenue ($m) 600 500 500 400 400 300 300 200 200 100 100 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q3
Slide 34: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
AP P E ND I X | Product Revenue Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 11% growth at CER to $6,345m in 9M 2025 33% decrease at CER to $665m in 9M 2025 31% growth at CER to $517m in 9M 2025 2,500 400 200 180 350 2,000 160 300 140 Product Revenue ($
Slide 35: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Fasenra Tezspire Saphnelo 19% growth at CER to $1,451m in 9M 2025 63% growth at CER to $770m in 9M 2025 47% growth at CER to $483m in 9M 2025 600 350 200 180 500 300 160 250 140 400 Product Revenue ($m) Product
Slide 36: BioPharmaceuticals: Respiratory & Immunology
AP P E ND I X | Product Revenue Performance BioPharmaceuticals: Respiratory & Immunology Breztri Symbicort 26% growth at CER to $906m in 9M 2025 0% decrease at CER to $2,180m in 9M 2025 350 900 800 300 700 250 600 Product Revenue ($m) Product Revenue ($m) 200 500 150 400 300 100 200 50 100 0 0 Q3 Q4
Slide 37: Rare Disease
AP P E ND I X | Product Revenue Performance Rare Disease Ultomiris Strensiq Koselugo 21% growth at CER to $3,453m in 9M 2025 19% growth at CER to $1,188m in 9M 2025 34% growth at CER to $498m in 9M 2025 1,400 500 250 450 1,200 400 200 1,000 350 Product Revenue ($m) Product Revenue ($m) Product Reven
Slide 38: Glossary
AP P E ND I X | Glossary Glossary 1L, 2L, 3L first-, second-, third-line ESC European Society of Cardiology NMR+ normalised membrane ratio positive 9M nine months ESMO European Society of Medical Oncology NRDL national reimbursement drug list AANEM American Association of Neuromuscular & Electrodiag
Slide 39: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis